CD274 and cancer: Blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4)–programmed cell death protein 1 (PD-1)–programmed cell death ligand 1 (PD-L1) inhibitory pathway has enabled remarkable clinical responses and revolutionized the treatments of different cancers [26–28].